{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:41Z","timestamp":1791588881484,"version":"4.3.4"},"reference-count":129,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["L232016"],"award-info":[{"award-number":["L232016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a cholestatic liver disease characterized by immune-mediated injury to small bile ducts. Although PBC is an autoimmune disease, the effectiveness of conventional immunosuppressive therapy is disappointing. Nearly 40% of PBC patients do not respond to the first-line drug UDCA. Without appropriate intervention, PBC patients eventually progress to liver cirrhosis and even death. There is an urgent need to develop new therapies. The gut\u2013liver axis emphasizes the interconnection between the gut and the liver, and evidence is increasing that gut microbiota and bile acids play an important role in the pathogenesis of cholestatic diseases. Dysbiosis of gut microbiota, imbalance of bile acids, and immune-mediated bile duct injury constitute the triad of pathophysiology in PBC. Autoimmune cholangitis has the potential to be improved through immune system modulation. Considering the failure of conventional immunotherapies and the involvement of gut microbiota and bile acids in the pathogenesis, targeting immune factors associated with them, such as bile acid receptors, microbial-derived molecules, and related specific immune cells, may offer breakthroughs. Understanding the gut microbiota\u2013bile acid network and related immune dysfunctions in PBC provides a new perspective on therapeutic strategies. Therefore, we summarize the latest advances in research of gut microbiota and bile acids in PBC and, for the first time, explore the possibility of related immune factors as novel immunotherapy targets. This article discusses potential therapeutic approaches focusing on regulating gut microbiota, maintaining bile acid homeostasis, their interactions, and related immune factors.<\/jats:p>","DOI":"10.3390\/ijms25084321","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:24:26Z","timestamp":1713176666000},"page":"4321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota\u2013Bile Acid\u2013Immunity Network"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7579-0592","authenticated-orcid":false,"given":"Ziqi","family":"Guo","sequence":"first","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5890-7835","authenticated-orcid":false,"given":"Ke","family":"Pang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9222-7327","authenticated-orcid":false,"given":"Chengzhen","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6976-1129","authenticated-orcid":false,"given":"Haifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9430-9874","authenticated-orcid":false,"given":"Dong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: Epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: Pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., and Ma, Y. (2021). The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed. Pharmacother., 140.","DOI":"10.1016\/j.biopha.2021.111754"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Blesl, A., and Stadlbauer, V. (2021). The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients, 13.","DOI":"10.3390\/nu13031018"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/hep.31228","article-title":"Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice","volume":"72","author":"Echeandia","year":"2020","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shi, Q., Yuan, X., Zeng, Y., Wang, J., Zhang, Y., Xue, C., and Li, L. (2023). Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease. Nutrients, 15.","DOI":"10.3390\/nu15102411"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/1462-2920.13401","article-title":"Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis","volume":"18","author":"Lv","year":"2016","journal-title":"Environ. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/hepr.13509","article-title":"Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis","volume":"50","author":"Furukawa","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1126117","DOI":"10.3389\/fimmu.2023.1126117","article-title":"Gut microbial profile of treatment-naive patients with primary biliary cholangitis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13714","DOI":"10.1111\/eci.13714","article-title":"Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid","volume":"52","author":"Han","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lammert, C., Shin, A., Xu, H., Hemmerich, C., O\u2019Connell, T.M., and Chalasani, N. (2021). Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis. FEMS Microbiol. Lett., 368.","DOI":"10.1093\/femsle\/fnab038"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Abe, K., Takahashi, A., Fujita, M., Imaizumi, H., Hayashi, M., Okai, K., and Ohira, H. (2018). Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198757"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19705","DOI":"10.1038\/s41598-021-99314-9","article-title":"Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis","volume":"11","author":"Kitahata","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00535-020-01664-0","article-title":"Emerging therapies for PBC","volume":"55","author":"Chascsa","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo","year":"2022","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","article-title":"The gut microbiota and host health: A new clinical frontier","volume":"65","author":"Marchesi","year":"2016","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2018.09.010","article-title":"Gut microbiota translocation promotes autoimmune cholangitis","volume":"95","author":"Ma","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jhep.2016.09.020","article-title":"The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation","volume":"66","author":"Schrumpf","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713647","DOI":"10.3389\/fimmu.2021.713647","article-title":"The Salivary Microbiota of Patients with Primary Biliary Cholangitis Is Distinctive and Pathogenic","volume":"12","author":"Lv","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lin, D., Wang, R., Luo, J., Ren, F., Gu, Z., Zhao, Y., and Zhao, L. (2020). The Core and Distinction of the Gut Microbiota in Chinese Populations across Geography and Ethnicity. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101579"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1225742","DOI":"10.3389\/fendo.2023.1225742","article-title":"Genetic predisposition of the gastrointestinal microbiome and primary biliary cholangitis: A bi-directional, two-sample Mendelian randomization analysis","volume":"14","author":"Luo","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","article-title":"Gut-liver axis: Barriers and functional circuits","volume":"20","author":"Pabst","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s10620-006-9544-z","article-title":"Abnormal intestinal permeability in primary biliary cirrhosis","volume":"51","author":"Feld","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/00365521.2010.539624","article-title":"Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis","volume":"46","author":"Zhao","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/08916930600623841","article-title":"Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis","volume":"39","author":"Haruta","year":"2006","journal-title":"Autoimmunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1572-0241.2002.05521.x","article-title":"Mucosal IgA defect in primary biliary cirrhosis","volume":"97","author":"Floreani","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jhep.2017.11.025","article-title":"Role of bile acids in the gut-liver axis","volume":"68","author":"Schneider","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","article-title":"Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases","volume":"16","author":"Li","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile Acids Activated Receptors Regulate Innate Immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000324144","article-title":"Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis","volume":"29","author":"Medina","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaut.2016.08.006","article-title":"Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis","volume":"75","author":"Hisamoto","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2208501","DOI":"10.1080\/19490976.2023.2208501","article-title":"Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis","volume":"15","author":"Pechlivanis","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cei.13198","article-title":"Pathogen infections and primary biliary cholangitis","volume":"195","author":"Tanaka","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","article-title":"Gut microbial metabolites as multi-kingdom intermediates","volume":"19","author":"Krautkramer","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Schulthess, J., Pandey, S., Capitani, M., Rue-Albrecht, K.C., Arnold, I., Franchini, F., Chomka, A., Ilott, N.E., Johnston, D.G.W., and Pires, E. (2019). The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity, 50.","DOI":"10.1016\/j.immuni.2018.12.018"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.4110\/in.2020.20.e15","article-title":"The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation","volume":"20","author":"Chen","year":"2020","journal-title":"Immune Netw."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s10620-012-2259-4","article-title":"Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription","volume":"57","author":"Wang","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1946366","DOI":"10.1080\/19490976.2021.1946366","article-title":"Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis","volume":"13","author":"Li","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83951","DOI":"10.18632\/oncotarget.13796","article-title":"Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis","volume":"7","author":"Gong","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Chen, L., Jiao, T., Liu, W., Luo, Y., Wang, J., Guo, X., Tong, X., Lin, Z., Sun, C., and Wang, K. (2022). Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. Cell Stem Cell, 29.","DOI":"10.1016\/j.stem.2022.08.008"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2304408","DOI":"10.1002\/advs.202304408","article-title":"Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid","volume":"11","author":"Wu","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in Kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor \u03ba light-chain enhancer of activated B cells (NF-\u03baB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sinha, S.R., Haileselassie, Y., Nguyen, L.P., Tropini, C., Wang, M., Becker, L.S., Sim, D., Jarr, K., Spear, E.T., and Singh, G. (2020). Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. Cell Host Microbe, 27.","DOI":"10.1016\/j.chom.2020.01.021"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T(H)17 and T(reg) cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: A Pilot Study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: Oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/liv.14069","article-title":"Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus","volume":"39","author":"Hegade","year":"2019","journal-title":"Liver Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2181930","DOI":"10.1080\/19490976.2023.2181930","article-title":"Cholestasis: Exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies","volume":"15","author":"Yu","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.29219\/fnr.v66.5459","article-title":"Lactobacillus plantarum Lp2 improved LPS-induced liver injury through the TLR-4\/MAPK\/NF\u03baB and Nrf2-HO-1\/CYP2E1 pathways in mice","volume":"66","author":"Chen","year":"2022","journal-title":"Food Nutr. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113433","DOI":"10.1016\/j.fct.2022.113433","article-title":"Ameliorative effect of Lactobacillus plantarum Lp2 against cyclophosphamide-induced liver injury in mice","volume":"169","author":"Zhang","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J. Food Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Scorletti, E., Afolabi, P.R., Miles, E.A., Smith, D.E., Almehmadi, A., Alshathry, A., Childs, C.E., Del Fabbro, S., Bilson, J., and Moyses, H.E. (2020). Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 158.","DOI":"10.1053\/j.gastro.2020.01.031"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"l4609","DOI":"10.1136\/bmj.l4609","article-title":"Clostridioides difficile: Diagnosis and treatments","volume":"366","author":"Guery","year":"2019","journal-title":"BMJ"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(19)31266-8","article-title":"The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications","volume":"394","author":"Allegretti","year":"2019","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Gong, C., Xu, J., Chen, D., Yang, B., Chen, Z., and Wei, L. (2023). Research Progress of Fecal Microbiota Transplantation in Liver Diseases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041683"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-023-39029-9","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_79","first-page":"974","article-title":"Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis","volume":"113","author":"Wang","year":"2022","journal-title":"Minerva Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"20406223221114198","DOI":"10.1177\/20406223221114198","article-title":"A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid","volume":"13","author":"Li","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int."},{"key":"ref_85","first-page":"796","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Levy, C., Kendrick, S., Bowlus, C.L., Tanaka, A., Jones, D., Kremer, A.E., Mayo, M.J., Haque, N., von Maltzahn, R., and Allinder, M. (2023). GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. Clin. Gastroenterol Hepatol., 21.","DOI":"10.1016\/j.cgh.2022.10.032"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: A double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"(2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/eji.202048589","article-title":"Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-\u03b3 and CX3CL1 production in primary biliary cholangitis","volume":"51","author":"Shimoyama","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: Regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Xiang, D., Yang, J., Liu, L., Yu, H., Gong, X., and Liu, D. (2023). The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115606"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am J Pathol"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Floreani, A., Gabbia, D., and De Martin, S. (2022). Obeticholic Acid for Primary Biliary Cholangitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102464"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Frisch","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Friedman, E.S., Li, Y., Shen, T.D., Jiang, J., Chau, L., Adorini, L., Babakhani, F., Edwards, J., Shapiro, D., and Zhao, C. (2018). FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. Gastroenterology, 155.","DOI":"10.1053\/j.gastro.2018.08.022"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"940688","DOI":"10.3389\/fimmu.2022.940688","article-title":"Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gut.2005.067389","article-title":"Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis","volume":"55","author":"Hruz","year":"2006","journal-title":"Gut"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat Rev Gastroenterol. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2019.06.003","article-title":"GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis","volume":"8","author":"Biagioli","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Duan, S., Li, X., Fan, G., and Liu, R. (2022). Targeting bile acid signaling for the treatment of liver diseases: From bench to bed. Biomed. Pharmacother., 152.","DOI":"10.1016\/j.biopha.2022.113154"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0029665120006916","article-title":"SCFA: Mechanisms and functional importance in the gut","volume":"80","author":"Marinelli","year":"2021","journal-title":"Proc. Nutr. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4983","article-title":"Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation","volume":"243","author":"Sheng","year":"2017","journal-title":"J. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"10984","DOI":"10.1021\/acs.jafc.7b04666","article-title":"Structure-Specific Effects of Short-Chain Fatty Acids on Plasma Cholesterol Concentration in Male Syrian Hamsters","volume":"65","author":"Zhao","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Shah, S., Fillier, T., Pham, T.H., Thomas, R., and Cheema, S.K. (2021). Intraperitoneal Administration of Short-Chain Fatty Acids Improves Lipid Metabolism of Long-Evans Rats in a Sex-Specific Manner. Nutrients, 13.","DOI":"10.3390\/nu13030892"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Fu, H.Y., Xu, J.M., Ai, X., Dang, F.T., Tan, X., Yu, H.Y., Feng, J., Yang, W.X., Ma, H.T., and Tu, R.F. (2022). The Clostridium Metabolite P-Cresol Sulfate Relieves Inflammation of Primary Biliary Cholangitis by Regulating Kupffer Cells. Cells, 11.","DOI":"10.3390\/cells11233782"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jhep.2019.05.030","article-title":"Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis","volume":"71","author":"Glaser","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jhep.2022.06.014","article-title":"NUDT1 promotes the accumulation and longevity of CD103(+) T(RM) cells in primary biliary cholangitis","volume":"77","author":"Huang","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.29371","article-title":"\u03b2-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis","volume":"67","author":"Thompson","year":"2018","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/bmjgast-2022-001001","article-title":"Feasibility, safety and tolerability of the CREB-binding protein\/\u03b2-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: An investigator-initiated, open-label, non-randomised, two-centre, phase 1 study","volume":"9","author":"Kimura","year":"2022","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Boicean, A., Birlutiu, V., Ichim, C., Brusnic, O., and Oni\u0219or, D.M. (2023). Fecal Microbiota Transplantation in Liver Cirrhosis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11112930"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Boicean, A., Birsan, S., Ichim, C., Boeras, I., Roman-Filip, I., Blanca, G., Bacila, C., Fleaca, R.S., Dura, H., and Roman-Filip, C. (2023). Has-miR-129-5p\u2019s Involvement in Different Disorders, from Digestive Cancer to Neurodegenerative Diseases. Biomedicines, 11.","DOI":"10.3390\/biomedicines11072058"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Huang, C., Xing, X., Xiang, X., Fan, X., Men, R., Ye, T., and Yang, L. (2020). MicroRNAs in autoimmune liver diseases: From diagnosis to potential therapeutic targets. Biomed. Pharmacother., 130.","DOI":"10.1016\/j.biopha.2020.110558"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/hep.30966","article-title":"MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice","volume":"71","author":"Kim","year":"2020","journal-title":"Hepatology"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:27:35Z","timestamp":1760106455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/8\/4321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":129,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25084321"],"URL":"https:\/\/doi.org\/10.3390\/ijms25084321","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]}}}